CD44 and neoplasm: Results showed that CTNND1+ tumor cells communicated with myeloid cells via ANXA1-FPR1/3, SIRPA-CD47, and LGALS9-CD44, which have been reported to involve in the inhibition of anti-tumor response 45-47.